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Background. The Aklavik H. pylori Project (AHPP) (www.canhelpworkinggroup.ca) is a community-driven
project examining Helicobacter pylori infection and its influence on health in a diverse Aboriginal community
in the Northwest Territories. Initial research revealed that 58% of 333 participants who underwent a urea
breath test (UBT) between 2007 and 2010 were H. pylori-positive. From 2008 to 2010, we offered treatment to
H. pylori-positive participants and 113 consented to this treatment.
Objective. We estimated H. pylori incidence in AHPP participants who initially tested negative and the
re-infection frequency in initially positive participants who were successfully treated to clear the infection.
Methods. Participants who were initially H. pylori-negative or negative after treatment during 2008 2010 were
eligible for inclusion. From November 2011 to June 2012, participants were offered a UBT and the samples
were analyzed using infrared spectroscopy (IRIS). Participants with a positive test result were classified as
new cases for estimating incidence among participants testing negative at baseline and re-infection among
those successfully treated for H. pylori infection.
Results. Among 38 initially negative participants, follow-up UBT showed that 33 remained negative, 3 were
positive, and 2 had uncertain status. The estimated incidence proportion during the follow-up period was
8.3% (95% CI: 1.8 22.0%). Among 43 participants with a negative post-treatment UBT, 41 remained negative
and 2 were positive. The estimated re-infection proportion during the follow-up period was 4.7% (95% CI:
0.6 16.0%). The frequency of new cases was similar in males and females. Aboriginal participants had a
combined re-infection/incidence rate of 2.4% per year (95% CI: 0.8 5.9% per year). All 9 non-Aboriginal
participants remained free from infection throughout the study period, as did all 23 participants aged 55 years
and above.
Conclusions. The AHPP has substantially reduced the burden of infection in Aklavik since 2008. Continued
monitoring, treatment, community engagement and knowledge translation activities are needed to ensure a
lasting benefit of the project.
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T
he Aklavik H. pylori Project (AHPP) is a com-
munity-driven project examining Helicobacter
pylori infection and its influence on health
in a diverse Aboriginal hamlet in the Northwest
Territories, conducted by the Canadian North Heli-
cobacter pylori (CANHelp) Working Group (http://www.
canhelpworkinggroup.ca). The CANHelp Working
Group brings together health care providers, Aboriginal
government representatives, the Aklavik Health Com-
mittee (AHC), and University of Alberta researchers
to address community concerns regarding the high
prevalence of H. pylori infection in Aklavik and the
association of this infection with stomach cancer.
Aklavik is an Arctic community of 633 people (accord-
ing to the 2011 census) including predominately Inuvia-
luit and Gwich’in peoples, along with smaller numbers of
Me ´tis, other First Nations and non-Aboriginal residents.
Overall project goals include investigating the impact
of H. pylori infection on Canadian Arctic communities;
identifying effective treatment strategies; developing
recommendations aimed at H. pylori infection manage-
ment; and effectively communicating research findings
to address community concerns (1,2). Currently, there is
no standard recommendation for community surveillance
of H. pylori infection or, more generally, for testing
and treating people who are not seeking medical care for
 INFECTIOUS DISEASE
Int J Circumpolar Health 2013. # 2013 Sally Carraher et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in
any medium, provided the original work is properly cited.
1
Citation: Int J Circumpolar Health 2013, 72: 21594 - http://dx.doi.org/10.3402/ijch.v72i0.21594
(page number not for citation purpose)relevant symptoms. However, the Maastricht IV/
Florence Consensus Report (3) on clinical manage-
ment of H. pylori infection recommends that, ‘‘A
screen-and-treat strategy of H. pylori should be explored
in communities with a significant burden of gastric
cancer.’’ With guidance from the locally organized
AHC, the AHPP developed approaches to participant
recruitment, enrolment, H. pylori screening, and treat-
ment in order to provide answers to community questions
about the infection and its potential health consequences.
During initial project planning, the AHC wanted all
residents of Aklavik to be invited to undergo screening
for H. pylori infection and treatment to be made available
to all participants testing positive. A treatment trial
conducted from 2008 to 2010 was designed to accom-
modate this request as well as to find effective treatments
for the strains of H. pylori that exist in Aklavik and
generate information that may be useful to regional
health authorities in future policy development.
Initial research revealed that of the 333 project parti-
cipants who were screened between November 2007 and
June 2010, 193 (58%) were H. pylori-positive by urea
breath test (UBT). From 2008 to 2010, the project offered
treatment to H. pylori-positive participants. The aim of
this new project component is to estimate the H. pylori
incidence and re-infection rates in Aklavik since the
treatment component of the AHPP was conducted.
Background
H. pylori are gram-negative spiral-shaped bacteria un-
iquely adapted to live in the stomach lining of humans.
H. pylori infection is often chronic and usually estab-
lished during childhood. While a majority of those with
chronic infection remain asymptomatic and free of
disease consequences, it has been estimated that chronic
H. pylori infection is responsible for more than 90% of
peptic ulcer disease cases in developing countries where
infection rates are high, and 65% of all gastric cancers
worldwide (4,5). While the bacterium’s pathogenic role
in initiating gastritis, peptic ulcers and gastric cancers
was described soon after H. pylori was identified in the
late 20th century, H. pylori research in the public health
sector has developed much more slowly. As the exact
transmission pathway(s) remain unconfirmed, much
current research aims to identify potential risk factors
for specific populations and communities and to investi-
gate the success and cost-effectiveness of particular sur-
veillance and treatment programs.
Epidemiologic studies across the globe present a strong
association of conditions, such as low socio-economic
status (SES), low levels of education and marginalized
ethnic status with H. pylori infection frequency (6).
Particularly in early life, poverty and related issues
including household crowding are commonly associated
with higher H. pylori prevalence (7,8). Relatively high
prevalence of H. pylori infection today exists in southeast
Asia, Africa, Central and South America, and through-
out the Arctic. Over the past 10 years, we have learned
that H. pylori infection and gastric cancers are much
more frequent in the Arctic regions of the United States,
Canada, Scandinavia and Russia compared to the
southern, more urban regions of these nations; and in
Greenland compared to Denmark (9,10).
Research in the AHPP has revealed that similar social
issues including income, ethnic status, parent education
level and household crowding are associated with
H. pylori infection (11). While we know that H. pylori
is highly prevalent in several remote Arctic communities
such as Aklavik, we know very little about H. pylori
incidence and re-infection rates in the North. A systema-
tic search reveals just one report of H. pylori incidence in
northern Canada   from a follow-up study of Aboriginal
children in northern Manitoba (12)   and no reports on
re-infection. As a large proportion of Aklavik’s commu-
nity participated in screening and treatment for H. pylori,
we were able to design an incidence and re-infection
study, having identified participants who were negative
for infection at the start of the study period. Our aim in
this analysis is to estimate the incidence of new H. pylori
infections in AHPP participants who initially tested
negative (baseline-negative) and the re-infection fre-
quency in initially positive participants who were success-
fully treated during the project (H. pylori-cleared).
Methods
In 2008, the AHPP offered UBT screening to all Aklavik
residents without restriction. During 2008 2010, 333
participants received a UBT to assess their infection
status. The ages of the 333 project participants ranged
from infancy to 80 years; 54% were female and 87% of
them were Aboriginals (56% Inuvialuit, 27% Gwich’in
and 4% other Aboriginal groups). A previous analysis
compared demographic characteristics of project partici-
pants and the community population (13). The charac-
teristics of the community population of Aklavik were
estimated by the community profile of 2006 census. The
findings suggested that the study population was older
and comprised a slightly greater proportion of females
than the community population.
From 2008 to 2010, the AHPP offered treatment to
H. pylori-positive participants and 113 consented to
treatment. The details and results of the trial have been
presented elsewhere (14). Participants were randomized
to receive either the standard triple therapy used across
Canada (rabeprazole 20 mg po bid, amoxicillin 1 g po bid
and clarithromycin 500 mg po bid for 10 days) or a
sequential therapy (10 days of rabeprazole 20 mg po bid,
days 1 5 amoxicillin 1 g po bid, days 6 10 clarithromycin
500 mg po bid and metronidazole 500 mg po bid),
unless antibiotic susceptibility testing showed evidence
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cases, individuals were randomized to receive either the
sequential therapy or a quadruple therapy (10 days
of bisthmuth 2 tablets qid, tetracycline 500 mg po qid,
metronidazole 500 mg po tid and rabeprazole 20 mg
po bid). Treatment success was assessed with a post-
treatment UBT at least 10 weeks after the completion
of treatment. Participants with treatment failures were
treated again with a different regimen and reassessed at
least 10 weeks after the completion of treatment.
For the new AHPP component aimed at estimating
H. pylori incidence and re-infection rates, participants
aged 15 years or above who were previously shown to
be free of H. pylori infection were eligible for inclusion.
All AHPP participants (n 179) who initially tested
H. pylori-negative (n 107) or were negative after
treatment (n 72) as of October 31, 2011 were invited
to undergo a repeated UBT to classify their current
H. pylori status. From November 2011 to June 2012,
we offered participants UBT screening for H. pylori
infection at the Susie Husky Health Centre in Aklavik.
Breath samples were analyzed using infrared spec-
troscopy (IRIS) at the University of Alberta. We classi-
fied UBT results as positive (delta-over-baseline test
values  4), negative (delta-over-baseline test values
from  2 to 2.5) or borderline (test values between 2.5
and 4). For borderline results or breath samples with
insufficient CO2 concentration, participants were asked
to repeat the test. If a sample with a sufficient CO2
concentration could not be obtained, the result was
considered unclassifiable and the participant was ex-
cluded from the analysis. When a repeat result was
borderline, the borderline classification was retained.
Participants with a positive test result were classified as
new cases: incident cases in the baseline-negative group
and re-infection cases in the H. pylori-cleared group.
We estimated two incidence measures: (a) the incidence
proportion (the number of new cases divided by the
number of infection-free participants who were retested
for the incidence study) pertaining to the time between
the negative UBT and the subsequent UBT and; (b) the
incidence rate (the number of new cases divided by the
person-time at risk). For estimating rates of incidence and
re-infection events, we define the person-time at risk as
the time period between the date of the last negative test
and the date of the follow-up test for each person,
subtracting half of this interval for participants with
new infection onsets. We calculated the incidence rates
by dividing the number of positive cases by the sum of
person-time at risk.
Given its community-based research design, the AHPP
is guided by community priorities. Previous analysis has
shown that H. pylori infection is less frequent among
non-Aboriginal community residents, and some commu-
nity members requested that we examine whether there is
a difference in infection frequency between the various
Aboriginal groups residing in Aklavik (classified as
‘‘Inuvialuit,’’ ‘‘Gwich’in’’ and ‘‘other Aboriginal’’). We
report estimated incidence and re-infection frequencies
with 95% confidence intervals (CI) for the total study
population (n 79) and for demographic subgroups by
age, sex and self-identified ethnicity. To compare inci-
dence across groups, we estimated incidence rate differ-
ences and 95% CI. As individual follow-up periods vary,
we do not compare incidence proportions in our analysis.
Results
We retested 81 participants for this study (Fig. 1). Of
these 81, age at the entry into this study period ranged
from 18 to 80 years (mean: 43, median: 44); 45 were
female (56%) and 66 self-identified as Aboriginal (81%).
Among the 38 participants who had tested negative on
initial screening, 33 remained negative on the follow-up
UBT, 3 were positive and 2 had uncertain results. In this
group, the estimated incidence proportion during the
follow-up period was 8.3% (95% CI: 1.8 22%). Among
the 43 participants with a previous negative post-
treatment UBT, 41 remained negative and 2 were posi-
tive. The estimated re-infection proportion during
the follow-up period was 4.7% (95% CI:  0.6 16.0%).
We report person-years and mean and median person
years-at-risk in Table I. As individual follow-up periods
vary, we report both incidence proportions and rates, but
only compared rates in our analysis.
Among the participants with follow-up results (n 79),
the estimated rate of newcaseswas 2.1% per year (Table I)
over an average follow-up of 3 years. Among people with
a negative UBT at study entry, the estimated incidence
rate was 1.8% per year; among people who had previously
cleared an infection, the estimated re-infection rate
was 2.4% per year. The rates in the 2 groups are similar,
with the 95% CI for the rate difference of  0.6% per
year comparing re-infection to new cases in those who
were infection-free at baseline ranging from  4.2 to 3.0%
per year.
Results across groups: sex, age, ethnicity
Among participants with classifiable follow-up results,
incidence proportions and rates (combining new cases
of infection in participants who were H. pylori-negative
at baseline and those who were successfully treated)
were estimated for categories of sex, age and self-reported
ethnic status. The estimated incidence proportion for the
follow-up period was 3.1% (95% CI: 0.1 16.0%) in males
and 8.5% (95% CI: 2.4 20%) in females. The estimated
incidence rate was 1.1% per year in males and 2.8% per
year in females. The estimated incidence rate difference
comparing males to females was  1.7% per year (95%
CI:  5.1 1.7% per year).
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starting at age 15 (15 34; 35 54; 55 and above). The rate
of new cases declined notably by age: 7.3% per year (95%
CI: 1.5 21.0% per year) in those aged 15 34; 1.6% per
year (95% CI: 0.2 5.8% per year) in those aged 35 54;
and 0 (97.5% CI: 0.0 5.0% per year) in those over age 55.
Aboriginal participants had a combined re-infection/
incidence rate of 2.5% (95%CI: 0.8 5.9% per year),
while all non-Aboriginal participants remained free
from infection during the study period. Of 41 self-
identified Inuvialuit participants, the rate of new cases
was 3.3% per year (95% CI: 0.9 8.4% per year); among
24 self-identified Gwich’in participants the rate of new
cases was 1.5% per year (95% CI: 0.4 8.2% per year). The
estimated incidence rate difference comparing Gwich’in
to Inuvialuit is  1.8% per year (95% CI:  6.1 2.5% per
year); the wide CI indicates that this study is too small to
accurately estimate the difference between these groups in
the rate of new cases. The 2 participants who identified as
‘‘other Aboriginal’’ remained free from infection during
the study period. Four out of 79 participants chose to not
report their ethnic status.
Discussion
Among participants in the AHPP aged 15 years and
above, we observed an incidence proportion of 6.3% over
an average follow-up of 3 years. In this population, the
rate of new cases of H. pylori infection declined notably
with age and was similar in males and females. Of note,
all participants in this study aged 55 years and above
remained free from infection throughout the study
period, as did all non-Aboriginal participants. Due to
the low incidence of new cases, we do not have enough
data in this population sample to precisely estimate
differences between ethnic and age groups. More
data are needed from additional Canadian Arctic
333 tested in initial UBT screening 
138 initially H. pylori (-)  194 initially H. pylori (+) 
1 uncertain result 
29 participants
aged < 15 
38 dropped out
126 treated for H. pylori
(113 enrolled in a
treatment trial) 
31 participants
aged < 15 
107 eligible for retesting
for new cases of H. pylori 
72 H. pylori (-) after 
treatment: eligible for
 retesting for reinfection
54 had positive,
uncertain, or no 
test results after 
treatment 
38 retested 43 retested
Fig. 1. Participation of the incidence/re-infection study among participants aged]15 years.
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population samples.
In this study, we have shown evidence suggesting that
most AHPP participants treated for H. pylori infection
remained free of infection during the follow-up period.
Thus, we can infer that there was a corresponding
decrease in the prevalence of H. pylori infection, bringing
the prevalence in Aklavik closer to the average seen in
southern Canada. This suggests a potential for reducing
the burden of infection in communities like Aklavik
through the application of screen and treat programs
with long-term follow up. Before recommending such a
strategy at the community level, however, a full assess-
ment of costs and benefits is needed. Widespread
antibiotic treatment may pose a risk to populations by
increasing antibiotic resistance among H. pylori strains as
well as other bacteria in the community. Our choice to
screen and offer treatment to all positive participants is
the result of consultation and consensus-building with
the AHC, and it is appropriate in this community for
a number of reasons. The AHPP has documented that
H. pylori infection is highly prevalent in Aklavik, as is
severe chronic gastritis and precancerous conditions of
the stomach. The pattern observed in Aklavik fits
with the observation that men in regional centres of
the Northwest Territories have three times the rate of
gastric cancer compared to men across Canada (15).
The AHPP is part of a research program that is gather-
ing similar data from other Canadian Arctic commu-
nities. In addition to assessing the burden of disease
from H. pylori infection in this region, we will assess
the cost-effectiveness of regional health care practices,
which currently include testing for and treatment of
H. pylori in patients presenting with a wide array of
gastric symptoms that can be caused by factors other
than H. pylori infection. The adoption of community
health strategies aimed at reducing health risks from
H. pylori infection requires careful generation and
analysis of the full array of evidence that must be
considered for effective public policy. An international
analysis of reported re-infection rates estimated summary
rates of 2.7% for developed countries (3,014 patients
followed for 24 60 months) and 13% for developing
countries (2,071 patients followed for 12 60 months)
(16,17), but there is extensive variation within these
groupings depending on the population studies. One
study, for example, estimated the re-infection rate at
1.8% per year in a population of Brazilian patients
with dyspeptic diseases (18). The AHPP is one of a
very few sources of data on H. pylori incidence and
re-infection rates in the circumpolar north. Our litera-
ture search identified just one report from this region.
A 2-year prospective study of urban Alaska Native
gastroenterology patients aged 18 years or above yielded
an estimated re-infection proportion following successful
treatment for H. pylori infection of 5.1% at 4 months,
increasing to 7.2% at 6 months, 10.3% at 1 year and
14.6% at 2 years (19). Among Aklavik project partici-
pants who were treated for H. pylori infection, the
estimated re-infection proportion was considerably lower
at 4.7% over an average of 2.6 years at risk. Some of this
difference may be attributable to differences between
gastroenterology patients and a community-based study
population as well as random variation; the Aklavik
Table I. Frequency of new H. pylori infections among participants in the Aklavik H. pylori Project, Northwest Territories, Canada
Incidence
Tested, N New cases
Person-years
at risk
Mean (median)-years
at risk
Proportion (%)
95% CI
Rate (% per year)
95% CI
Total 79* 5 239.3 3.0 (3.0) (6.3) 2.1 14 (2.1) 0.7 4.9
Baseline-negative 36* 3 126.4 3.5 (3.8) (8.3) 1.8 22 (2.4) 0.5 6.9
H. pylori-cleared 43 2 112.9 2.6 (2.8) (4.7) 0.6 16 (1.8) 0.2 6.4
Male 32 1 94.8 3.0 (3.0) (3.1) 0.1 16 (1.1) 0.3 4.7
Female 47 4 144.6 3.1 (2.8) (8.5) 2.4 20 (2.7) 0.03 5.9
Age: 15 34 years 15 3 41.1 2.7 (2.8) (20) 4.3 48 (7.3) 1.5 21.0
Age: 35 54 years 41 2 124.7 3.0 (3.0) (4.9) 0.6 17 (1.6) 0.2 5.8
Age: 55 years and above 23 0 73.5 3.2 (3.0) (0) 0 15
$ (0) 0 5.0
$
Inuvialuit
% 41 4 121.5 3.0 (2.9) (9.8) 2.7 33 (3.3) 0.9 8.4
Gwich’in
% 23 1 68.3 3.0 (2.8) (4.3) 0.1 22 (1.5) 0.04 8.2
Other Aboriginal
% 2 0 7.6 3.5 (3.8) (0) 0 84
$ (0) 0 49.0
$
Non-Aboriginal
% 9 0 28.6 3.2 (3.2) (0) 0 34
$ (0) 0 13.0
$
*Excludes 2 with uncertain results.
$One-sided, 97.5% confidence interval.
%Of 79 with classifiable results, excludes number of patients who declined to identify ethnicity.
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Alaskan study population, so if H. pylori incidence
decreases with age, differences in age distribution would
not explain the observed difference re-infection frequen-
cies. While H. pylori infection is generally more prevalent
throughout North American Arctic communities for
which we have data, compared to southern Canada and
the United States, these findings suggest variation across
Arctic communities, and demonstrate the need for data
from additional communities to add to our knowledge of
H. pylori infection and its related human health outcomes
in the North.
Conclusions
This incidence and re-infection study indicates that the
screening and treatment components of the AHPP have
substantially reduced the prevalence of H. pylori infection
among project participants since the treatment compo-
nent began in 2008. The CANHelp Working Group is
continuing to collect data on determinants of treatment
success as well as benefits of treatment in order to achieve
our collaborative team’s goals of addressing community
concerns about health risks from H. pylori infection,
and ultimately reducing these risks. Participant follow-up
in Aklavik combined with epidemiological and ethno-
graphic assessments of associated risk factors, and on-
going community engagement and knowledge translation
activities, are continuing in order to assess the long-term
implications of community-wide test-and-treat programs
for controlling H. pylori infection.
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